| Title |
Taste and smell perception and quality of life during and after systemic therapy for breast cancer
|
|---|---|
| Published in |
Breast Cancer Research and Treatment, February 2018
|
| DOI | 10.1007/s10549-018-4720-3 |
| Pubmed ID | |
| Authors |
Y. C. de Vries, S. Boesveldt, C. S. Kelfkens, E. E. Posthuma, M. M. G. A. van den Berg, J. Th. C. M. de Kruif, A. Haringhuizen, D. W. Sommeijer, N. Buist, S. Grosfeld, C. de Graaf, H. W. M. van Laarhoven, E. Kampman, R. M. Winkels |
| Abstract |
The purpose of the study was to assess self-reported taste and smell perception after chemotherapy in breast cancer patients compared with women without cancer, and to assess whether taste and smell perception is associated with quality of life after the end of chemotherapy. We included 135 newly diagnosed breast cancer patients who completed chemotherapy and 114 women without cancer. Questionnaires on taste, smell, and quality of life were completed shortly after and 6 months after chemotherapy (patients) or at two moments with 6 months' time window in between (comparisons). Self-reported taste and smell perception were significantly lower in patients shortly after chemotherapy compared to the comparison group. Most patients recovered 6 months after chemotherapy, although patients who were still receiving trastuzumab then reported a lower taste and smell perception compared to patients who were not. A lower self-reported taste and smell were statistically significantly associated with a worse quality of life, social, emotional, and role functioning shortly after chemotherapy. Six months after chemotherapy, taste and smell were statistically significantly associated with quality of life, social and role functioning, but only in patients receiving trastuzumab. Most taste and smell alterations recovered within 6 months after the end of chemotherapy for breast cancer, but not for patients receiving trastuzumab. These results highlight the importance of monitoring taste and smell alterations during and after treatment with chemotherapy and trastuzumab, as they may impact quality of life. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 67% |
| Kenya | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 67% |
| Members of the public | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 105 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 105 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 21 | 20% |
| Student > Master | 14 | 13% |
| Researcher | 11 | 10% |
| Student > Postgraduate | 5 | 5% |
| Student > Ph. D. Student | 5 | 5% |
| Other | 11 | 10% |
| Unknown | 38 | 36% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 23 | 22% |
| Nursing and Health Professions | 22 | 21% |
| Agricultural and Biological Sciences | 7 | 7% |
| Biochemistry, Genetics and Molecular Biology | 3 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 2% |
| Other | 7 | 7% |
| Unknown | 41 | 39% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 June 2018.
All research outputs
#14,377,572
of 23,025,074 outputs
Outputs from Breast Cancer Research and Treatment
#3,107
of 4,683 outputs
Outputs of similar age
#187,866
of 330,329 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#45
of 81 outputs
Altmetric has tracked 23,025,074 research outputs across all sources so far. This one is in the 35th percentile – i.e., 35% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,683 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one is in the 31st percentile – i.e., 31% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 330,329 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 81 others from the same source and published within six weeks on either side of this one. This one is in the 43rd percentile – i.e., 43% of its contemporaries scored the same or lower than it.